Increased VEGF expression is common in NSCLC and is associated with adverse clinical outcomes; therefore, addition of bevacizumab to standard chemotherapy regimens may be beneficial. Indeed ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Because of the near-simultaneous approval of new metastatic RCC therapies that act on VEGF and the HIF transcription cascade, Trx inhibitors such as MGd should be explored as potential candidates ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared ...

control). At protein level, Hif-1α did not change significantly with hypoxia or re-oxygenation. Vegf protein did not increase in retina or choroid with hypoxia or re-oxygenation. P65 was ...

Dr. Heather Wakelee examines the increasingly routine use of adjuvant therapy for patients with early stage non-small-cell lung cancer. Experts And Viewpoints, July 17, 2008 Oral VEGF Therapies in ...

Previously, the HIF-2α inhibitor belzutifan (Welireg; Merck) was approved for treatment of adult patients with advanced RCC following treatment with an immune checkpoint inhibitor and a VEGF ...